8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Feb 3, 2014)

Filed February 3, 2014For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on February 3, 2014, primarily to report its financial results for the fourth quarter and the full year ended December 31, 2013. The filing incorporates by reference a press release that details these financial outcomes. Investors should note that this information is crucial for understanding the company's recent performance and financial health. While the 8-K itself is a brief reporting document, the attached press release (Exhibit 99.1) is the key source of detailed financial figures and management commentary. This provides insights into revenue, profitability, and potentially guidance for the upcoming fiscal year. Investors relying on this filing should pay close attention to the specifics within the press release to assess the company's operational success and outlook.

Key Highlights

  • 1Edwards Lifesciences filed an 8-K on February 3, 2014.
  • 2The filing's primary purpose is to report financial results for Q4 and full-year 2013.
  • 3A press release detailing the financial results is furnished as Exhibit 99.1.
  • 4The press release is incorporated by reference into the 8-K.
  • 5The filing provides information on the company's financial condition and results of operations.
  • 6Scott B. Ullem, Corporate Vice President and Chief Financial Officer, signed the report.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Edwards Lifesciences' financial results for the fourth quarter and the full year ended December 31, 2013, to the public and the SEC.

The detailed financial results are provided in the press release dated February 3, 2014, which is furnished as Exhibit 99.1 and incorporated by reference into this 8-K filing.

No, the information furnished under Item 2.02 and Exhibit 99.1 is specifically noted as not being deemed 'filed' for the purposes of the Securities Exchange Act of 1934, as amended. This means it is for informational purposes and doesn't carry the same legal implications as a formally filed document.

The report was signed on behalf of Edwards Lifesciences Corporation by Scott B. Ullem, who holds the position of Corporate Vice President and Chief Financial Officer.